Evidence map›Paper›PMID 24740791›Full record

ArticleAmerican journal of physiology. Renal physiology2014

Mechanisms of AT1a receptor-mediated uptake of angiotensin II by proximal tubule cells: a novel role of the multiligand endocytic receptor megalin.

Xiao C Li, Jia L Zhuo

Erratum issuedAbstract read
In one paragraph

Article in American journal of physiology. Renal physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. The role of lipocalin-2 in age-related macular degeneration (AMD).Cellular and molecular life sciences : CMLS · 2020
    Review
  6. Review
  7. Review
  8. Article
  9. The effect of A1 adenosine receptor in diabetic megalin loss with caspase-1/IL18 signaling.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Xiao C LiLaboratory of Receptor and Signal Transduction, Department of Pharmacology and Toxicology, Cardiovascular and Renal Research Center, Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi.
Jia L ZhuoLaboratory of Receptor and Signal Transduction, Department of Pharmacology and Toxicology, Cardiovascular and Renal Research Center, Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi jzhuo@umc.edu.
University of Mississippi Medical Center · US

Funding

Role of Intracrine Angiotensin II in Kidney CellsR01DK067299 · NIDDK · UNIVERSITY OF MISSISSIPPI MED CTR · PI Jia Long Zhuo · 2004 to 2026
$6.5M
Role of Proximal Tubule NHE3 in Angiotensin II-induced HypertensionR01DK102429 · NIDDK · UNIVERSITY OF MISSISSIPPI MED CTR · PI ZHUO, JIA LONG · 2014 to 2021
$2.5M
Novel Roles of Intracrine Angiotensin II in Proximal Tubule CellsR56DK067299 · NIDDK · HENRY FORD HEALTH SYSTEM · PI ZHUO, JIA LONG · 2009 to 2009
$352k
NIDDK NIH HHS 2R01DK067299NIDDK NIH HHS 2R56DK067299NIDDK NIH HHS 5R01DK067299NIDDK NIH HHS R01 DK067299NIDDK NIH HHS R01 DK102429NIDDK NIH HHS R56 DK067299
6 · The paper itself

Abstract

The present study tested the hypothesis that the multiligand endocytic receptor megalin is partially involved in the uptake of ANG II and downstream signaling responses in mouse proximal tubule cells (mPCT) by interacting with AT1a receptors. mPCT cells of wild-type (WT) and AT1a receptor-deficient (AT1a-KO) mice were treated with vehicle, the AT1 receptor blocker losartan (10 μM), or a selective megalin small interfering (si) RNA for 48 h. The uptake of fluorescein (FITC)-labeled ANG II (10 nM, 37°C) and downstream signaling responses were analyzed by fluorescence imaging and Western blotting. AT1a receptors and megalin were abundantly expressed in mPCT cells, whereas AT1a receptors were absent in AT1a-KO mPCT cells (P < 0.01). In WT mPCT cells, FITC-ANG II uptake was visualized at 30 min in the cytoplasm and in the nuclei 1 h after exposure. Losartan alone completely blocked the uptake of FITC-ANG II, whereas megalin siRNA inhibited only 30% of the response (P < 0.01). The remaining FITC-ANG II uptake in the presence of megalin siRNA was completely abolished by losartan. ANG II induced threefold increases in phosphorylated MAP kinases ERK1/2 and a onefold increase in phosphorylated sodium and hydrogen exchanger 3 (NHE3) proteins, which were also blocked by losartan and megalin-siRNA. By contrast, losartan and megalin siRNA had no effects on these signaling proteins in AT1a-KO mPCT cells. We conclude that the uptake of ANG II and downstream MAP kinases ERK1/2 and NHE3 signaling responses in mPCT cells are mediated primarily by AT1a receptors. However, megalin may also play a partial role in these responses to ANG II.

Indexed as

EndocytosisAngiotensin IIAngiotensin II Type 1 Receptor BlockersAnimalsCells, CulturedEnzyme ActivationExtracellular Signal-Regulated MAP KinasesFluorescein-5-isothiocyanateKidney Tubules, ProximalLigandsLosartanLow Density Lipoprotein Receptor-Related Protein-2MiceMice, Inbred C57BLMice, KnockoutPhosphorylationAgtr1a protein, mouseAngiotensin IIAngiotensin II Type 1 Receptor BlockersExtracellular Signal-Regulated MAP KinasesFluorescein-5-isothiocyanateLigandsLosartanLow Density Lipoprotein Receptor-Related Protein-2Lrp2 protein, mouseReceptor, Angiotensin, Type 1Slc9a3 protein, mouseSodium-Hydrogen Exchanger 3Sodium-Hydrogen Exchangersangiotensin IIAT1 receptor-mediated endocytosiskidneymegalinproximal tubule

Identifiers

PMID24740791
PMCPMC4101628
OpenAlexW2062627307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.